 |
Mr. Dentzer is President & CEO of the company. He was appointed to this position in September 2018. Mr. Dentzer, who joined Curis in 2016, was promoted earlier in 2018 to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT and investor and public relations.
Previous experience:
CFO, Dicerna Pharmaceuticals
CFO, Valeritas
CFO, Amicus Therapeutics
VP Corporate Controller, Biogen
Education:
MBA, University of Chicago
BA, Boston College
 |
Dr. Martell has served as the company’s Head of Research & Development since 2018. He joined the company as a member of the Board of Directors in 2011.
Previous experience:
Assoc Chief of Hematology/Oncology, Tufts Medical Center
Chief Medical Officer, Tesaro
Chief Medical Officer, MethylGene
Director, Oncology Global Clinical Research, Bristol Myers Squibb
Deputy Director, Medical Science Unit, Bayer
Education:
PhD, University of Michigan
MD, Wayne State University
BA, Kalamazoo College
Certifications:
Board Certified in Internal Medicine and Medical Oncology
 |
Mr. Steinkrauss has served as Chief Financial Officer of the company since September 2019. Mr. Steinkrauss joined Curis in August 2016 as Corporate Controller and Senior Director of Finance, and prior to his appointment served as Treasurer and Vice President of Finance.
Previous experience:
Director, Technical Accounting and Reporting, OvaScience
Senior Manager, Technical Accounting, Cubist Pharmaceuticals (acquired by Merck)
Manager, PricewaterhouseCoopers LLP
Education:
MS, Boston College
BS, Boston College
Certifications:
Certified Public Accountant, Commonwealth of Massachusetts